B Cells with Regulatory Function in Human Diseases.
Yuhua Wang,Xiaozhe Han
2014-01-01
Autoimmune Diseases and Therapeutic Approaches Open Access
Abstract:It has long been recognized that B cells with Regulatory function (BREGs) play an important role in human diseases. However, the majority of the studies on BREGs have been conducted in murine models. The studies of BREGs in human disease are limited but of great importance since they provide valuable insights into the potential B cell-directed therapeutics in humans. A number of reports described human B cells that produce IL-10, [1-3] as potential BREGs and findings suggest that these human BREGs are potent generators of regulatory T cells (Treg) [4, 5]. Spontaneous IL-10 production by blood mononuclear cells is dramatically higher in untreated autoimmune disease patients than in healthy controls [6]. Yet, current knowledge regarding human B-cell production of IL-10 provides diverse results that are difficult to unify in a coherent model. IL-10 producing B cells were diffusely scattered throughout the B-cell lineage and not restricted to either the immature transitional B-cell compartment (CD24hiCD38hi) or the memory B-cell compartment (IgD+CD27+). These B cells, obtained from human peripheral blood or spleen, were induced by stimulation with oligonucleotides that contained CpG motifs and anti-Ig and that these cells inhibited T-cell proliferation in an IL-10–dependent manner. However, it is still unclear to what extent IL-10-producing B cells express other cytokines and how this may affect their BREG cell functionality [7]. Despite the reports that B cells in humans have functions analogous to those of BREGs described in various experimental mouse models of disease [8, 9], it remains unclear whether human BREGs exist naturally or they need to be induced following any immune stimulation. This review is to summarize the current knowledge about the phenotypic markers of human BREGs and their function in autoimmune- and non-autoimmune diseases. Phenotypic Markers of human BREGs CD19+-CD25+B cells are the first subset of human B cells previously suggested to have a regulatory role. They were characterized as a phenotypically and functionally distinct subset by expressing high levels of immunoglobulin's compared with CD19+-. CD25- B cells, while they lacked the ability to secrete them. CD27 and CD80 which have previously been shown to enhance antigen-presenting cell function are strongly expressed on this B-cell subpopulation. They could present antigen more efficiently to allogeneic CD4+T cells in Mixed Lymphocyte Reaction (MLR) compared with CD25−B cells, a function that was attributed to the high expression level of CD25. Finally the differential regulation of CD25 expression via selective TLR ligands suggests a role for CD25+B cells in bridging innate and acquired immune responses [10]. In addition, CD25+B cells secreted significantly higher levels of inhibitory cytokine IL-10 versus CD25- B cells. In contrast, TGF-β1 secretion was similar between the CD25+ and CD25+sub-populations [11]. CD25+B cells were found to display a high activated and mature phenotype in RA and SLE patients compared to healthy controls. This subset was sensitive to IL-2 which was found to affect auto-reactive responses and suggested to have a regulatory role in autoimmune diseases. CD19+CD25 high B cells were reported to be significantly higher in patients suffering from ANCA-related vasculitis in remission than in active patients [12]. However, the functional properties of this subset of B cells remained obscure. CD19+CD24hiCD38hi (so-called immature transitional B cells) was identified by Blair and coworkers in the peripheral blood of healthy individuals as another human regulatory B-cell subset. The CD24hiCD38hiB-cell population was capable of suppressing IFN-γ and TNF- α secretion by anti-CD3–stimulated T helper cells, and this suppression was dependent on IL-10 and CD80/CD86 co-stimulation. This subset is able to suppress the differentiation of Th1 effector cells in a CD40 dependent way. In addition, it was also shown that their suppressive capacity was IL-10, but not TGF-β dependent. When analyzed in SLE patients, these cells were functionally impaired as incapable of suppressing Th1 cells compared to their ability in healthy individuals [8, 11]. CD19+CD25highCD86high IL-10high TGF-βhigh cells were defined by Kessel as “Breg cells”. B cells were purified from human Peripheral Blood Mononuclear Cells (PBMCs) of healthy individuals and were stained with fluorescent mAbs to CD19, CD25, CD86 and mAbs to IL-10 and TGF-β. Gaiting on IL-10high expressing cells, phenotypic analyzes revealed that IL-10 high expressing cells were also CD25high, CD86high, and TGF-βhigh. The co-culture of these Breg cells with autologous stimulated CD4+T cells decreased significantly (in a dose-dependent way) the proliferative capacity of CD4+T cells. Furthermore, Foxp3 and CTLA-4 expression in Treg cells were enhanced by non-stimulated and further by ODN-CD40L stimulated Breg cells. The regulatory function of Breg cells on Treg cells was mainly dependent on a direct contact between Breg and Treg cells, but was also TGF-β but not IL-10 dependent. In conclusion, human Breg cells decrease the proliferation of CD4+T cells and also enhance the expression of Foxp3 and CTLA-4 in Treg cells by cell-to-cell contact [13]. CD24+CD27+ B cells were characterized as a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells by Iwata and named it as “human B10 and progenitor B10 cells”. B10 cells were functionally identified by their ability to express cytoplasmic IL-10 after 5 hours of ex vivo stimulation, whereas progenitor B10 (B10pro) cells required 48 hours of in vitro stimulation before they acquired the ability to express IL-10 [14]. CD19+ CD1d+ CD5+ B cell were found in the patients with tuberculosis with stronger suppressive activity than such cells from healthy donors. Furthermore, the frequency of CD19+CD1d+CD5+ B cells in peripheral blood was inversely correlated with that of Th17 cells in patients with tuberculosis [15]. CD1d+ B cells were reported by Correale and coworkers that this subset B cells were present in the peripheral blood of helminth-infected patients with Multiple Sclerosis (MS), producing high levels of IL-10 in response to CD40 ligation. B cells from healthy controls and helminth-infected patients with MS, were able to suppress T-cell proliferation in an IL-10-dependent manner in vitro while uninfected patients with MS didn't have this suppressive function [9].